Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Fortis AI-Powered Hybrid Cath Lab Opens in New Delhi
Fortis AI-powered hybrid cath lab at Fortis Escorts, New Delhi combines robotic angiography and AI imaging. An installation, not outcome evidence.
Cologuard Colorectal Cancer Screening Study Results
Cologuard colorectal cancer screening study: Abbott reports 54% lower adjusted incidence linked to completion. Observational, so not proof of cause.
Orthocell Remplir Prostate Surgery: Early Pilot Results
Orthocell Remplir prostate surgery pilot: 5 patients, no device-related complications in about 12 months. Preliminary, and not proof of benefit.
Keytruda Biosimilar FDA Review: FYB206 BLA Accepted
FDA has accepted the Zydus and Formycon FYB206 BLA for review, the first publicly announced Keytruda biosimilar filing. Decision possible in Q3 2027.
At-Home Heart Failure Treatment Study: 21-Patient Data
In a 21-patient, single-arm study, 18 patients with worsening heart failure were treated at home with Lasix ONYU. Results, device facts and key limits.
TissueCypher Barrett’s Esophagus Test: 83% Low Risk
Castle Biosciences reports TissueCypher sorted 83% of Barrett's patients as low risk and shifted management for 96%. What the data show and do not.
Envoy Medical Acclaim Cochlear Implant: 2 of 4 FDA Modules
Envoy Medical filed the second of four PMA modules for its fully implanted Acclaim cochlear implant. What was submitted, what is unknown, and what is next.
Sun Pharma ₹10,000 Crore NCD Issue: Down From ₹15,000 Cr
Sun Pharma's board approved up to ₹10,000 crore of NCDs, below the ₹15,000 crore proposed, and director Gautam Doshi resigned. What is known and unknown.
Obuprazine Schizophrenia Clinical Trial: Phase 2b Data
Obuprazine (TRTL-107) beat placebo at all three doses in a 363-patient Phase 2b trial in China. Key PANSS results, safety gaps and next steps.
Medicine Price Control India 2026: SC Eyes Wider Cap
The Supreme Court asked why India's 30% cancer drug margin cap should not extend to other medicines. No universal cap yet; hearing returns 27 October.